Why did MoonLake's operating expenses surge in Q2 2024?

MoonLake Immunotherapeutics's operating expenses surged in Q2 2024 due to **Increased Research and Development Costs** and **Higher Professional Fees**:

1. **Research and Development Costs**: The significant increase in R&D costs was primarily driven by the company's ongoing efforts to develop its product pipeline, particularly for MLTX-3155, a drug candidate for the treatment of Hidradenitis Suppurativa. The company's investment in research and development activities, such as clinical trials and personnel, has been on the rise, which directly impacts the operating expenses.
2. **Professional Fees**: MoonLake has been engaging with various professional service providers, including consultants, advisors, and experts, to support its business development and strategic initiatives. The fees associated with these services have contributed to the overall increase in operating expenses.

In summary, the surge in operating expenses in Q2 2024 is a result of MoonLake's strategic investments in R&D and professional fees to advance its pipeline and business objectives.